Harvestfield Healthcare FZE has commenced commercial production of Synera DuoForte, a next-generation insecticide-treated net, at its manufacturing facility in the Harvestfield Free Trade Zone, Ogun State, Nigeria. The facility, which is wholly Nigerian-owned, began operations on 13 September 2026 and is already supplying a World Bank-funded programme reaching 31 states. This development marks a significant milestone in Nigeria's capacity to manufacture critical malaria prevention interventions locally.
The Harvestfield facility is the first of its kind in Nigeria to manufacture dual active ingredient long-lasting insecticidal nets of the pyrethroid-chlorfenapyr class. The company produces Synera DuoForte under a manufacturing agreement with GDM Health Products, which developed and owns the product. Synera DuoForte combines a pyrethroid with a second insecticide that works through a different mode of action, making it effective in areas where mosquito populations have developed resistance to pyrethroid insecticides.
The World Health Organisation recommends dual active ingredient nets for areas with established pyrethroid resistance. Synera DuoForte is a WHO-prequalified product, and the Harvestfield manufacturing site in Ogun State is an approved manufacturing location under that prequalification. The facility is also certified by the National Agency for Food and Drug Administration and Control (NAFDAC) and ISO certified, providing a foundation for manufacturing nets for national malaria programmes and other health interventions.
Jon Bastow, a representative of GDM Health Products, expressed pleasure in partnering with Harvestfield to bring Synera DuoForte to Nigeria, the country with the biggest global malaria burden. The partnership supports the prequalification of Harvestfield's Ogun State manufacturing facility to make Synera DuoForte. This development aligns with the Federal Government's focus on strengthening domestic production of health products under the Renewed Hope agenda for health.
Muhammad Ali Pate, the coordinating Minister of Health and Social Welfare, emphasized the importance of building Nigeria's capacity to manufacture its own health products. He noted that a Nigeria-based facility producing next-generation insecticide-treated nets to international standards, and already supplying programmes across 31 states, is a key capability the Renewed Hope agenda aims to build. Harvestfield's move into manufacturing builds on over two decades of experience in Nigeria's vector control sector.
The transition from distribution to manufacturing strengthens the domestic supply chain for insecticide-treated nets, reducing dependence on overseas supply schedules and ocean journeys. Local production creates greater capacity to respond to evolving malaria control needs and insecticide resistance patterns. Abdul Mukhtar, presidential Initiative for Unlocking the Healthcare Value Chain (PVAC), highlighted the significance of local manufacturing in strengthening Nigeria's healthcare value chain.
The investment creates local manufacturing, technical, quality, and regulatory capabilities that can support the production of other health products over time. For Harvestfield, the net manufacturing facility represents the first platform in a broader effort to build healthcare manufacturing capability in Nigeria. This development is aligned with the Presidential Initiative for Unlocking the Healthcare Value Chain (PVAC) and the Nigeria First procurement policy.
Key points
- Harvestfield Healthcare's new facility is the first wholly Nigerian-owned manufacturing site for dual active ingredient long-lasting insecticidal nets.
- The facility has already started supplying a World Bank-funded programme reaching 31 states.
- The production of Synera DuoForte supports Nigeria's health security and the Renewed Hope agenda for health.
